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Results: Alveolar hypoxia led to a significantly higher
amount (124%) and activity (234%) of protein phospha-
tase (PP) 2A in membrane preparations from LV
compared to control. Serum levels of several cytokines
were assayed, and a pronounced increase in IL-18 was
observed. In isolated cardiomyocytes, treatment with
IL-18 increased the amount and activity of PP2A, and
reduced phosphorylation of phospholamban at Ser16 to
54% of control.
Conclusions: Our results indicate that the diastolic
dysfunction observed in alveolar hypoxia might be
caused by increased levels of interleukin-18 inducing an
increase in PP2A in the heart and thereby a reduction in
phosphorylation of phospholamban at Ser16.
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Low lung function is associated with increased risk for
cardiovascular disease (CVD). Atherosclerotic plaques in
the internal carotid artery (ICA) is a known risk factor
for stroke. The objective for this study was to examine
the prevalence of atherosclerotic plaques in the ICA in
subjects with COPD and to examine potential associa-
tions between the occurrence of atherosclerotic plaques
in the ICA and different lung function parameters.
The invited study population consisted of 450
subjects (41% men), aged 46-78 years, who comprised a
subset of a population based sample. A complete lung
function test including diffusing capacity of carbon
monoxide was performed. COPD was diagnosed in
subjects who had a ratio of FEV1/VC <0.7. Ultrasound
was used to screen the ICA bilaterally for plaques.
The prevalence of atherosclerotic plaques in the ICA
in the COPD group was 64%, in the non-COPD group 47%.
Most of the differences in lung function among subjects
with and without atherosclerotic plaques in the ICA
could not be seen after adjustments for different risk
factors for atherosclerosis. Interestingly though,
differences in residual volume and diffusing capacity of
carbon monoxide remained after such adjustments,
suggesting a possible association between lung
parenchymal changes and atherosclerotic plaques in the
ICA.
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A large part of the costs of chronic obstructive
pulmonary disease (COPD) are due to comorbidities (1).
Little is known concerning the costs related to co-
morbidities in COPD in the Scandinavian countries.
We present the baseline data of a 1-year prospective
survey of the health economic aspects of COPD in
Norway (EconCOPD) (2). 136 smokers without COPD
(controls) and 90 smokers with COPD stage 2+ (cases) (3)
were included from the general population in spring
2005, based on spirometry results in 2003-2004. In
addition we included 250 hospital patients with COPD
stage 2+ (patients). Participants reported comorbidities
and self-reported healthcare costs (drugs, visits to
healthcare providers, aid equipment, help with
activities of daily living and rehabilitation) the
preceding 3 months at baseline.
The mean FEV1 % predicted was 95.3%, 64.5% and
47.2% among controls, cases and patients respectively.
There were more men in all three groups of
participants, and more current smokers among the
patients. 50% of controls, 66% of cases and 74% of
patients reported comorbid conditions. Subjects with
comorbidities reported larger healthcare costs (p<0.05)
within all three groups of participants except within the
cases.
Future analyzes on the EconCOPD data will enable
calculation of costs generated by excess comorbidity in
COPD.
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